Dare Bioscience (DARE)
(Delayed Data from NSDQ)
$3.28 USD
+0.02 (0.61%)
Updated Sep 23, 2024 03:55 PM ET
After-Market: $3.23 -0.05 (-1.52%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Income Statements
Fiscal Year end for Dare Bioscience, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 3 | 10 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 3 | 10 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 34 | 41 | 39 | 27 | 14 |
Income After Depreciation & Amortization | -31 | -31 | -39 | -27 | -14 |
Non-Operating Income | 1 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -30 | -31 | -39 | -27 | -14 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | -31 | -39 | -27 | -14 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | -31 | -39 | -27 | -14 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -31 | -31 | -39 | -27 | -14 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -31 | -31 | -39 | -27 | -14 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 7.27 | 7.05 | 5.09 | 2.51 | 1.30 |
Diluted EPS Before Non-Recurring Items | -4.20 | -4.44 | -7.56 | -10.92 | -11.65 |
Diluted Net EPS (GAAP) | -4.20 | -4.44 | -7.56 | -10.92 | -11.64 |
Fiscal Year end for Dare Bioscience, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.02 | 0.01 | 1.81 | 1.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.02 | 0.01 | 1.81 | 1.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 7.38 | 6.03 | 6.98 | 9.39 | 8.99 |
Income After SG&A, R&D, and Dept/Amort Expenses | -7.36 | -6.02 | -5.17 | -8.39 | -8.99 |
Non-Operating Income | 20.27 | -0.73 | 0.11 | 0.10 | 0.23 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 12.91 | -6.76 | -5.06 | -8.30 | -8.76 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 12.91 | -6.76 | -5.06 | -8.30 | -8.76 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 12.91 | -6.76 | -5.06 | -8.30 | -8.76 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 8.48 | 8.37 | 7.02 | 7.59 | 7.20 |
Diluted EPS Before Non-Recurring Items | 1.52 | -0.84 | -0.72 | -1.08 | -1.20 |
Diluted Net EPS (GAAP) | 1.52 | -0.84 | -0.84 | -1.08 | -1.20 |